Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Saved in:
Bibliographic Details
Title: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
Authors: Senna M; Lahey Hospital and Medical Center, Burlington, MA, USA., Soung J; Southern California Dermatology, Inc, Santa Ana, CA, USA.; Harbor - University of California, Los Angeles, Torrance, CA, USA., Figueras I; Bellvitge Hospital, University of Barcelona, Barcelona, Spain., King B; Dermatology Physicians of Connecticut, Fairfield, CT, USA., Kinoshita-Ise M; Department of Dermatology, Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo, Japan., Hanna S; University of Toronto, Toronto, ON, Canada., Wu W; Huashan Hospital, Fudan University, Shanghai, China., Wajsbrot D; Pfizer Inc, Groton, CT, USA., Woodworth D; Pfizer Inc, Collegeville, PA, USA., Wolk R; Pfizer Inc, Groton, CT, USA., Chaudhry A; Pfizer Inc, Collegeville, PA, USA., Lejeune A; Pfizer Inc, Paris, France., Tran H; Pfizer Inc, New York, NY, USA. Helen.Tran@pfizer.com.
Source: American journal of clinical dermatology [Am J Clin Dermatol] 2026 Mar 31. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1888
DOI:10.1007/s40257-026-01029-y